Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.66 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | PTGES | O14684 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14135805 | 0.91 | SLC10A1 (0.60) | SLC10A1CA9PTGESHSD11B1PTPN1 | |
| SCHEMBL14135799 | 0.89 | PTPN1 (0.54) | SLC10A1PTPN1 | |
| SCHEMBL15074887 | 0.84 | SLC10A1 (0.75) | SLC10A1CA9PTGES | |
| SCHEMBL23766686 | 0.82 | GPBAR1 (0.53) | SLC10A1CA9HSD11B1 | |
| Betulin Diacetate SCHEMBL14134382 | 0.82 | SLC10A1 (0.85) | SLC10A1CA9PTGESPTPN1 | |
| SCHEMBL22571118 | 0.82 | SLC10A1 (0.71) | SLC10A1CA9 | |
| Betulin Diacetate SCHEMBL10001907 | 0.82 | SLC10A1 (0.85) | SLC10A1CA9PTGESPTPN1 | |
| SCHEMBL24223619 | 0.82 | SLC10A1 (0.71) | SLC10A1CA9 | |
| Betulin Diacetate SCHEMBL21800881 | 0.82 | SLC10A1 (0.85) | SLC10A1CA9PTGESPTPN1 | |
| SCHEMBL24223618 | 0.82 | SLC10A1 (0.71) | SLC10A1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170348324-A1 | DERIVATIVES OF BETULIN | GLAXOSMITHKLINE LLC (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348324-A1 | DERIVATIVES OF BETULIN | BET1, TMPO, PGGT1B | SLC10A1 112/4885CA9 3476/4885PTGES 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.